Legend Biotech Corp Market Cap ($3.99 Billion)
Market Cap & Net Worth: Legend Biotech Corp (LEGN)
Legend Biotech Corp market cap. Legend Biotech Corp (NASDAQ:LEGN) has a market capitalization of $3.99 Billion ($3.99 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4002 globally and #1420 in its home market, demonstrating a 14.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Legend Biotech Corp's stock price $21.63 by its total outstanding shares 194488413 (194.49 Million). Also see cash efficiency ratio of Legend Biotech Corp for how efficiently the company converts equity into cash flow.
Legend Biotech Corp Market Cap History (2020–2026)
Legend Biotech Corp market cap history from 2020 to 2026. Data shows change from $5.48 Billion to $4.21 Billion (-8.04% CAGR). Check LEGN stock price and chart for real-time trading data and today's change.
Index Memberships
Legend Biotech Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.15% | #106 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #465 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.22% | #67 of 263 |
Weight: Legend Biotech Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Legend Biotech Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Legend Biotech Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Legend Biotech Corp (LEGN) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.11x
Legend Biotech Corp's market cap is 4.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $5.48 Billion | $75.00 Million | -$266.37 Million | 73.02x | N/A |
| 2021 | $9.07 Billion | $68.83 Million | -$403.58 Million | 131.71x | N/A |
| 2022 | $9.71 Billion | $117.00 Million | -$446.35 Million | 82.98x | N/A |
| 2023 | $11.70 Billion | $285.14 Million | -$518.25 Million | 41.04x | N/A |
| 2024 | $6.33 Billion | $627.24 Million | -$177.03 Million | 10.09x | N/A |
| 2025 | $4.23 Billion | $1.03 Billion | -$296.80 Million | 4.11x | N/A |
Competitor Companies of LEGN by Market Capitalization
Companies near Legend Biotech Corp in the global market cap rankings as of November 1, 2026. Also see Legend Biotech Corp asset portfolio for a full breakdown of the balance sheet.
Key companies related to Legend Biotech Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Legend Biotech Corp (2020–2026)
Market capitalization of Legend Biotech Corp from 2020 to today. Between 2020 and today, Legend Biotech Corp's market cap moved from $5.48 Billion to $ 4.21 Billion, with a yearly change of -8.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.21 Billion | -0.51% |
| 2025 | $4.23 Billion | -33.19% |
| 2024 | $6.33 Billion | -45.92% |
| 2023 | $11.70 Billion | +20.53% |
| 2022 | $9.71 Billion | +7.10% |
| 2021 | $9.07 Billion | +65.52% |
| 2020 | $5.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Legend Biotech Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.99 Billion USD |
| MoneyControl | $3.99 Billion USD |
| MarketWatch | $3.99 Billion USD |
| marketcap.company | $3.99 Billion USD |
| Reuters | $3.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more